First Tracks Biotherapeutics is trading 10.02% higher at $39.91 on October 20, 2026, amid biotech-sector momentum. - No new company-specific announcement explaining the move was identified; positive celiac-disease trial results and a $200 million private placement were announced earlier in October. - The supplied sector context shows XBI up about 2.1%, amid acquisition activity and positive clinical-trial news. Shares also rose 5.28% on October 19, extending the advance.